Sporadic inclusion body myositis (sIBM) presents with a characteristic ... pathways might prove helpful in arresting disease progression. sIBM is often misdiagnosed as polymyositis or other ...
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...
New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...
Myopathic (myo = muscle, pathy = disease) conditions can include polymyositis, dermatomyositis, inclusion body myositis, and various myopathies ... including the heart. The rate of progression of the ...
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...
The phenotypes under analysis included three “classic” IIM subgroups — defined as dermatomyositis, polymyositis and inclusion body myositis — as well as overlap myositis, in which there is ...
Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors. Abcuro announced that it has obtained $200 million in Series C financing, led by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback